"Remestemcel-L intravenous infusions have been evaluated in over 1,100 patients in various clinical trials mainly in relation to acute graft versus host disease (aGVHD) in children".
I'm under the impression the 1,100 patients refer to lung trial only.
If one were to add up all patients in all msb trials you would get a figure over 3000 with no adverse health outcomes reported to date.
As to whats going on with sp.
Australian investors very skittish when investors in US markets can't make up their minds!
When results come and money starts to flow Aussie Institutions will take an interest and then on route to CSL type valuation,imo.
Both Patience and patients required.
- Forums
- ASX - By Stock
- Ann: Inflammatory Lung Disease Outcomes For Presentation at ISCT
"Remestemcel-L intravenous infusions have been evaluated in over...
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.13 |
Change
-0.025(2.17%) |
Mkt cap ! $1.284B |
Open | High | Low | Value | Volume |
$1.15 | $1.16 | $1.11 | $7.363M | 6.488M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 94863 | $1.13 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.13 | 5000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 85863 | 1.125 |
3 | 60500 | 1.120 |
3 | 49858 | 1.115 |
10 | 234700 | 1.110 |
3 | 20500 | 1.105 |
Price($) | Vol. | No. |
---|---|---|
1.130 | 1000 | 1 |
1.135 | 15000 | 2 |
1.140 | 10000 | 1 |
1.150 | 27892 | 3 |
1.155 | 25000 | 1 |
Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |